Forbes Has Amgen in Its Cross-Hairs

Forbes Magazine just published a scathing critique of Amgen's lobbying crusade, which has won it ever-higher reimbursements for its dialysis drug, Epogen, even while it was harming patients. Hats off to reporter Kerry Dolan, and not just because she quotes me. She had the story pretty much knocked by the time she got around to calling.